Aeruginosin 865, a compound extracted from the terrestrial cyanobacterium Nostoc sp. Luke ová 30/93, represents the inaugural aeruginosin-type peptide to incorporate a fatty acid and a carbohydrate moiety. It functions by inhibiting the translocation of NF-kB to the nucleus, thereby exerting an anti-inflammatory effect.

Aeruginosin 865 (pretreatment with 0.1-100 μg/mL) shows significant inhibition of IL-8 (EC 50 =3.5 μg/mL) and ICAM-1 (EC 50 =50.0 μg/mL) in hTNF-α-stimulated HLMVECs in a concentration-dependent manner. Aeruginosin 865 does not affect cell viability, even at much higher concentration in HeLa, HepG2 cells[1]. Aeruginosin 865 (100-200 μM) shows high-dose cytotoxicity in Mouse fibrosarcoma cells and with no cytotoxic effect in NIH/3T3 cells[2]. .